Canaccord Genuity Group Raises CeriBell (NASDAQ:CBLL) Price Target to $33.00

CeriBell (NASDAQ:CBLL) had its price target raised by equities research analysts at Canaccord Genuity Group from $31.00 to $33.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 12.36% from the company’s previous close.

A number of other analysts have also issued reports on CBLL. Canaccord Genuity Group started coverage on shares of CeriBell in a research note on Tuesday, November 5th. They set a “buy” rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. started coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price objective on the stock. TD Cowen began coverage on CeriBell in a research report on Tuesday, November 5th. They set a “buy” rating and a $31.00 target price on the stock. Bank of America started coverage on CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price target for the company. Finally, William Blair assumed coverage on CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating on the stock. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $31.60.

CeriBell Price Performance

Shares of CBLL stock traded down $0.87 during mid-day trading on Monday, reaching $29.37. The company’s stock had a trading volume of 46,246 shares, compared to its average volume of 194,420. CeriBell has a 12-month low of $23.00 and a 12-month high of $32.54.

CeriBell (NASDAQ:CBLL) last issued its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to the consensus estimate of $17.06 million. As a group, research analysts forecast that CeriBell will post -2.46 earnings per share for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.